ANSWERING YOUR QUESTIONS
Frequently Asked Questions
Alzheimer's disease FAQ
What is Alzheimer disease ?
Alzheimer’s disease is a progressive neurodegenerative condition that causes deterioration of memory and other important mental functions. It is the most common cause of dementia in older people, accounting for approximately 60 to 70% of cases.
How is cognitive deterioration characterized ?
It is characterized by progressive loss of memory, especially for recent events in the early stages, as well as difficulties in language, problem solving, and carrying out daily tasks.
What are the causes ?
In addition to memory loss, symptoms include confusion, changes in mood and behavior, disorientation in time and space, language difficulties, and decreased motivation.
What are the symptoms ?
How the disease progresses
The disease usually progresses slowly over several years, first affecting short-term memory, then gradually long-term memory, the ability to think and reason, and finally, the ability to perform the simplest everyday tasks
How is the diagnosis made ?
It is based on clinical history, neurological examinations, cognitive tests, and sometimes brain imaging studies to rule out other causes of dementia.
FAQ Projet Ronoma
The company RonomA, a biotechnology company resulting from Norman academic research which aims to bring to the market a new innovative treatment for neurodegenerative diseases. The first research work primarily targeted Alzheimer’s disease.
The small lead molecule patented and developed by RonomA as a potential new therapeutic solution is the result of more than 10 years of research. Indeed, the first molecules were synthesized in 2013 by professors Christophe ROCHAIS and Patrick DALLEMAGNE and were the subject of numerous scientific articles. It is known as Donecopride, although today the optimized molecule is now called Neocopride.
A molecule is said to be pleiotropic or Multi Target Directed Ligands (in English) when it has the capacity to act simultaneously on several targets. Regarding Neocoprid, this molecule acts on both acetylcholinesterase (by inhibiting it) and the serotonin 5HT-4 receptor (by activating it).
The action on its two targets at the level of the brain will allow a whole synergy of beneficial effects in the areas impacted by the disease and therefore for the patients. Indeed, in the models that we used, Neocoprid was able to limit neuronal loss, reduce neuroinflammation but above all our molecule made it possible to stimulate synaptogenesis (formation of synapse connection between two neurons) as well as the formation of neurites. (the cellular extension of the neuron).
Currently, most molecules in development or molecules on the market only target one molecular target involved in Alzheimer’s disease. However, this disease is a multifactorial disease induced by numerous causes (amyloid peptide, Tau protein, oxidative stress, etc.). It is therefore unlikely that treatments will be fully effective by acting on a single target. This is why we chose to develop our molecule which has a dual action.
The development of a drug is a very long and very expensive process. Our next step is to finalize the regulatory preclinical trials which will then allow us to carry out the first administrations in humans. We hope to achieve these studies sometime in 2025.
All questions for the laboratory